DXB 5.62% 42.0¢ dimerix limited

Ann: Positive Top-Line Results in DKD Phase 2 Clinical Study, page-303

  1. 1,993 Posts.
    lightbulb Created with Sketch. 443
    one thing is clear that Dimerix can't go to Phase 3 trial for DKD themselves.... it's too expensive for them to do...

    I think a lot depends on the sub analysis on the future direction of DKD indication...
 
watchlist Created with Sketch. Add DXB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.